Drug Profile


Alternative Names: Beta-lactamase capsule - Ipsat; Bioengineered β-lactamase - Ipsat; Ipsat P1A

Latest Information Update: 15 May 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ipsat Therapies
  • Class Antibacterials; Enzymes
  • Mechanism of Action Beta lactamase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Intestinal infections

Most Recent Events

  • 03 Dec 2012 Synthetic Biologics acquires P1A from Prev AbR LLC
  • 12 Nov 2012 Discontinued - Phase-II for Intestinal infections (prevention) in Russia (PO)
  • 12 Nov 2012 Discontinued - Phase-II for Intestinal infections (prevention) in Ukraine (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top